Asking patients to tell us what we don’t know

Lisa Willemse
Dec 21, 2015 · 5 min read
Photo: Lisa Willemse

Twenty-six people had gathered in the room. One, a patient with a spinal cord injury, arrived in a wheel chair. Another had Huntington’s disease. Two of the women had multiple sclerosis and another had vision loss.

In all, eight of those assembled had first-hand experience living with a severe, debilitating illness. All were patient advocates, some of whom worked for their representative health charities. They joined the remaining 18, representing health charities and organizations focused on research and clinical translation.

They came to listen and to share their expertise and perspectives on clinical trials and regenerative medicine, something that strangely doesn’t happen very often.

It’s not hard to imagine why not: although everyone in the room wants the same thing — treatments or cures for injury and disease — each group has its own focus. Different branches of the same tree, reaching in the same direction, but not necessarily touching. We amass a great deal of knowledge and experience that doesn’t simply jump from one side of the tree to the other. We sometimes forget that it doesn’t.

That separation can create barriers to communication: jargon or assumptions about the level of knowledge — dangerous things if it makes patients more susceptible to the risks of unproven therapies.

Event organizers, the Ontario Institute for Regenerative Medicine (OIRM) and Clinical Trials Ontario (CTO), brought everyone together in Toronto to understand the gaps in knowledge in order to understand how they could align communications efforts to enable patients, medical professionals and health charities obtain better information and make better decisions about their health. The day was bookended by presentations from OIRM and CTO to provide background information and set the stage for the focused discussions.

Even within this small group, there were a range of experiences. One MS patient spoke openly about her travels to the United States and her hope that paying for unconventional therapies that are unapproved in Canada would stall or perhaps even reverse the progression of her disease. Another woman, who had taken part in a stem cell clinical trial in Ottawa, is now considered cured of a rare and aggressive neurological disorder.

But, despite many differences, some clear commonalities emerged. The first part of the discussion asked what information was needed about clinical trials to help patients. Patient advocates and health charity staff provided these insights (order not indicative of importance):

  1. Ensure specialists and other health care practitioners are kept up-to-date with clinical trial information, since these are where they turn first for advice.

The second part of the discussion focused on stem cells specifically, as asked what information is needed about stem cell therapies available through clinical trials and those available outside clinical trials. Feedback included these main points (order not indicative of importance):

  1. Scientists need to be better trained to provide direct, jargon-free answers about stem cell clinical trials and future therapy timelines for patients. As one participant commented, “We’re kind of in the wild west where we have a lot of scientists who are new to the clinical space and they need to have the tools to communicate more effectively as experts.”

As one patient advocate exclaimed: “I didn’t know what I didn’t know! I had filled out an application online was accepted to a stem cell clinic in Panama. The cost per treatment was $21,000 and I didn’t know what questions to ask!”

The many questions about stem cell treatments outside of Canada indicated that this was an area of both interest and concern on behalf of patient advocates. They included questions regarding success rates, availability of funds for post-treatment in Canada, where treatments can be obtained and what preparation should be done in advance of treatment. In essence, they were asking “How do I assess a therapy being offered by a clinic outside of Canada?”

One reason it is challenging to answer this question is that there is no systematic way of assessing the quality or accuracy of the information, since most unregulated clinics do not publish data, so there is no way to establish an effective or safe protocol. However, it was obvious that the importance of published data and treatment protocols is not yet fully understood by the patient audience, and thus presents another item for consideration that was not explicitly raised.

Many of the 26 people who were in that Toronto room had never had the opportunity to share or listen to the questions and experiences that framed understanding and perceptions of clinical trials and stem cell treatments. The organizers walked away with a long list of ideas, some feasible, others less so, that they can use to improve patient engagement and to create better communications products. The patient advocates and health charities will know that their insights were valuable and that further engagement will follow.

Note: Names of patient advocates and other identifying information have been omitted for privacy considerations.

The Expression

Short features on stem cells and regenerative medicine…

Medium is an open platform where 170 million readers come to find insightful and dynamic thinking. Here, expert and undiscovered voices alike dive into the heart of any topic and bring new ideas to the surface. Learn more

Follow the writers, publications, and topics that matter to you, and you’ll see them on your homepage and in your inbox. Explore

If you have a story to tell, knowledge to share, or a perspective to offer — welcome home. It’s easy and free to post your thinking on any topic. Write on Medium

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store